Li Huibo, Wang Jia, Hu Yang, Hu Wei, Li Jun, Liu Yang, Zhao Rongsheng, Zhu Yi Zhun
School of Pharmacy, Faculty of Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Pharmaceuticals (Basel). 2025 Feb 24;18(3):312. doi: 10.3390/ph18030312.
: This bibliometric analysis investigates recent research trends in biologics and small molecules for treating inflammatory bowel disease (IBD) based on literature from the past decade. This cross-sectional study involved analyzing data retrieved from the Web of Science Core Collection (WoSCC) database to examine the evolution and thematic trends of biological agents and small-molecular drugs for IBD conducted between 1 January 2014, and 20 September 2024. VOSviewer software was utilized to assess co-authorship, co-occurrence, co-citation, and network visualization, followed by a further discussion on significant sub-themes. From 2014 to 20 September 2024, the annual number of global publications increased by 23%, reflecting an acceleration in research activity. The journal "Inflammatory Bowel Diseases" published the highest number of manuscripts (579 publications) and garnered the most citations (13,632 citations), followed by the "Journal of Crohn's & Colitis" (480 publications) and "Alimentary Pharmacology & Therapeutics" (250 publications). The United States led in productivity with 1943 publications and 66,320 citations, with UC San Diego (291) and authors Sandborn and Vermeire (180) topping the list. The co-occurrence cluster analysis of the top 100 keywords resulted in the formation of six distinct clusters: Disease Mechanisms, Drug Development, Surgical Interventions, Therapeutic Drug Monitoring (TDM), Immunological Targets, and Emerging Therapies. Burst terms (TNF-α inhibitors, JAK inhibitors, and trough-level optimization) highlight trends toward personalized biologics and small-molecule regimens. The bibliometric analysis indicates that IBD therapeutic research and clinical applications focus on biologics and small molecules, with research trends leaning toward precise therapy conversion or the combination in non-responders. Future work will assess monotherapy, the combination, and conversion therapies and investigate new drugs targeting inflammatory pathways.
这项文献计量分析基于过去十年的文献，研究了用于治疗炎症性肠病（IBD）的生物制剂和小分子药物的最新研究趋势。这项横断面研究涉及分析从Web of Science核心合集（WoSCC）数据库检索到的数据，以考察2014年1月1日至2024年9月20日期间用于IBD的生物制剂和小分子药物的演变及主题趋势。利用VOSviewer软件评估共同作者关系、共现情况、共被引情况及网络可视化，随后对重要子主题进行进一步讨论。从2014年到2024年9月20日，全球出版物的年数量增长了23%，反映出研究活动的加速。《炎症性肠病》杂志发表的手稿数量最多（579篇出版物），获得的引用次数也最多（13632次引用），其次是《克罗恩病与结肠炎杂志》（480篇出版物）和《消化药理学与治疗学》（250篇出版物）。美国在产出方面领先，有1943篇出版物和66320次引用，加州大学圣地亚哥分校（291篇）以及作者桑德伯恩和韦尔米尔（180篇）位居榜首。对前100个关键词的共现聚类分析形成了六个不同的聚类：疾病机制、药物研发、手术干预、治疗药物监测（TDM）、免疫靶点和新兴疗法。突发词（肿瘤坏死因子-α抑制剂、JAK抑制剂和谷浓度优化）突出了个性化生物制剂和小分子治疗方案的趋势。文献计量分析表明，IBD治疗研究和临床应用聚焦于生物制剂和小分子药物，研究趋势倾向于在无反应者中转向精准治疗或联合治疗。未来的工作将评估单药治疗、联合治疗和转换治疗，并研究针对炎症通路的新药。
